Neoplasms

Updated: July 11, 2024

Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

tegafur

Indicated for Malignant neoplasm
The maximum dose is 1 g/m² orally every day, generally combined with uracil

tegafur

Indicated for Malignant neoplasms
Administer 1 to 3 g/m² intravenously every day for five days

rovadicitinib (Investigational Drug)

Myeloproliferative Neoplasm (MPN) (off-label)
Currently in phase 2 clinical trial in the treatment of Myelofibrosis and also in patients with palpable splenomegaly and MPN
The dose used in the study is 5 mg four times per day or 10 mg two times a day for four weeks, which showed good therapeutic response, which was well tolerated and is safe :

Dose Adjustments

Limited data is available

asnuciclib

It is an investigational drug studied for its effectiveness to treat primary leukemia

Future Trends